Launch of Wegovy pill is core to Novo Nordisk's growth, says Guggenheim's Seamus Fernandez

? (Anchor) 00:00.190

for warren its first ever GLP one pill guggenheim partner seamus fernandez joins us now he is a firm 's managing director and pharma analyst seamus great to have you with us

Seamus Fernandez (Managing Director and Pharma Analyst) 00:09.110

nice to see

? (Anchor) 00:10.150

you does this change the competitive landscape at all with eli lilies or for coming on and and some other competitors coming you know down the pike

Seamus Fernandez (Managing Director and Pharma Analyst) 00:19.310

that's a great question i mean i think it doesn't necessarily change the competitive landscape that dramatically but it does give novo an opportunity to gain a foothold in the pill market that's going to develop we expect very quickly it really depends on how much novo can

Seamus Fernandez (Managing Director and Pharma Analyst) 00:36.430

supply of wegovy pill which you know i think is still a little bit uncertain so that's something that we think the company is going to need to clarify with investors broadly speaking but you know there is a very substantial opportunity for any pill to basically expand in this

Seamus Fernandez (Managing Director and Pharma Analyst) 00:55.750

market and we think both wegovy pill and lily 's or for glyphron are going to be successful in growing the market

? (Anchor) 01:03.670

but they've already started manufacturing north carolina and they made a point that it's going to be end to end the active ingredient will be manufactured at that north carolina plant is there a question in your mind about the ability of novo to manufacture to meet demand i mean

? (Anchor) 01:18.070

it is a more complicated molecule than or for glyphron to manufacture so do you think that there is a question mark

Seamus Fernandez (Managing Director and Pharma Analyst) 01:25.550

so it's slightly more complicated in manufacture but i think the other factor here is also that there's a lot more product necessary to actually put into this pill in order for it to be as effective as an injectable so i think that's the factor that's really kind of coming into

Seamus Fernandez (Managing Director and Pharma Analyst) 01:43.150

play here is that you almost need seventy times as much of the molecule to actually go into the gut so that it can cross into the circulation where an injectable actually just gets sort of right into your system right into your system and works very very quickly and and very

Seamus Fernandez (Managing Director and Pharma Analyst) 02:02.520

effectively

? (Anchor) 02:03.790

there are also you know some constraints in terms of when you take the pill you know during the day how much water you can have when you can then take other medication or or have other food et cetera is this just going to be sort of a a test i mean when consumers try this and

? (Anchor) 02:19.390

then or for glyphron comes on the market shortly are they just going to switch in the end i mean how much is this really novo nordisk 's ability to gain back some of the market share it may have lost to eli lilly

Seamus Fernandez (Managing Director and Pharma Analyst) 02:32.630

yeah i think there that's the ultimate test this year in twenty twenty six i think we're really going to know and learn what consumers actually prefer do they prefer a very easy pill to take that could be slightly less well tolerated you know i i think those are the outstanding

Seamus Fernandez (Managing Director and Pharma Analyst) 02:52.790

questions at this point lilly does have a great you know experience with its own lilly direct and so i think lilly has shown its ability to market to the consumer very very effectively this is actually novos test this year to see if they can kind of live up to the expectations

Seamus Fernandez (Managing Director and Pharma Analyst) 03:14.590

and live up to the path that lily has to some degree laid with their own lilly direct availability